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INTRODUCTION
Cow’s milk allergy (CMA) is the most common food allergy 
among infants in Europe, with prevalence rates estimated in 
the range of 2% and 3%.1 Although previous reports stated a 
good prognosis with a high rate of spontaneous resolution,2,3 
recent studies suggest varying results (13%-37%) to the rate of 
resolution during childhood.1,4
The accepted management of CMA is the total avoidance of 
milk to prevent adverse reactions, which can be life-threaten-
ing.5,6 Nevertheless, milk exclusion involves a wide dietary re-
striction, which leads to negative nutritional, social, psycholog-
ical, and economic consequences.7 Moreover, because of cow’s 
milk (CM) ubiquity, avoidance cannot be always guaranteed, 
and accidental reactions may occur.8 For this reason, CM oral 
immunotherapy (OIT) appears as a promising approach for 
CMA treatment.9 As in any other food OIT protocol, CM-OIT 
starts with administration of milk at very low doses, which are 
increased up to the usual intake (around 200 mL). Thereafter, it 
is given daily in a maintenance dosage.10 The main goal of CM-
OIT is to increase the threshold dose which triggers symptoms, 
protecting patients against reactions on accidental exposure. In 
addition, it allows the inclusion of milk in the patient’s diet, 
with the subsequent benefit in nutrition and quality of life.
Previous studies on CM-OIT have shown desensitization rates 
of 36%-92% after a wide array of protocols.11 However, there is 
still a lack of sufficient evidence regarding long-term efficacy, 
safety, impact on quality of life, and cost-effectiveness of these 
procedures. Thus, CM-OIT is considered nowadays an experi-
mental treatment not ready yet for clinical practice.12,13
Currently, there is little knowledge regarding immunological 
changes and mechanisms subjacent to CM-OIT. So far, the dif-
ferent studies performed have highlighted an increase in the 
levels of allergen-specific IgG4 after successful CM-desensitiza-
tion.14-17 Nevertheless, in cases of the allergen-specific IgE re-
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sponse, the results are somehow controversial.17-20 Although 
these observations clearly indicate immune-deviation, to the 
best of our knowledge, there is only 1 report available charac-
terizing the T-cell response of milk allergic patients before and 
after a CM-OIT protocol.21
The objective of this study was to evaluate the safety and effi-
cacy to induce clinical desensitization to CM of an OIT protocol 
in a pediatric population with CMA. In addition, with the aim 
of adding some insights into the immunological mechanisms 
subjacent to CM-OIT, the immune responses against β-casein, 
one of the main milk allergens, of Peripheral Blood Mononu-
clear Cells (PBMCs) from CMA patients before and after the 
protocol were evaluated. For that purpose, a panel of cytokines 
covering Th1, Th2, and Treg responses, together with allergen-
specific IgE and IgG4 levels were assessed. For comparison, a 
population of nonallergic donors from the same age-range was 
included in the study.
MATERIALS AND METHODS
Ethics statement
All human samples/procedures were obtained/performed 
with written consent from the next of kin, caretakers, or guard-
ians on behalf of the minors/children involved in the study. The 
Bioethics Committees from Consejo Superior de Investigacio-
nes Científicas and Hospital Universitario La Paz (Madrid, 
Spain) approved all experiments.
Patient selection
Subjects were recruited from the Allergology Service at Infan-
ta Sofia Hospital (Madrid, Spain). All the children enrolled in 
the CMA group were patients diagnosed through a compatible 
clinical history, positive skin prick test (≥3 mm of negative con-
trol) and positive CM-, casein- (CN), α-lactalbumin (α-La)-, 
and/or β-lactoglobulin (β-Lg)-specific IgE. In addition, all the 
subjects had experienced a positive reaction during a single 
blind food challenge (SBFC) with commercial semi-skimmed 
ultra-high temperature-treated (UHT) pasteurized CM (3.3% 
protein) the month before the beginning of the study. A group 
of nonallergic children, with no detectable IgE against a broad 
panel of the most common allergens, was also included in the 
study.
CM-OIT protocol
The protocol was carried out at the Allergology Day Unit of 
the Infanta Sofía Hospital, under the direct supervision of the 
medical and nursing staff, and with all the equipment and ma-
terial required for the treatment of possible allergic reactions 
that could occur during the procedure. The CM-OIT protocol 
was performed with commercial semi-skimmed UHT CM, as 
described in Table 1. The starting dose of the protocol was the 
previous one to the highest tolerated dose during the SBFC. 
Once the patients were able to tolerate 4 mL of undiluted CM 
without symptoms, an open challenge with baked goods con-
taining milk was performed. Similarly, after tolerating 10 mL, 
patients were challenged with milk-containing cold meat, with 
milk chocolate after 15 mL, liquid fermented milk (Actimel®) 
after 60 mL, yogurt after 100 mL, cow’s cream cheese after 120 
mL, and finally with goat and ewe’s milk cheeses after 200-240 
mL. Between visits, patients were advised to daily ingest at 
home the maximum dose tolerated during their last visit to the 
unit. When needed, premedication with oral antihistamines 
was given to patients who developed adverse reactions during 
the protocol, in order to control the symptoms. Reaction severi-
ty was assessed according to Clark and Ewan.22 In cases of mod-
erate reactions, these were pharmacologically treated and the 
protocol was restarted in the following week at the previously 
tolerated dose. Hence, the length of the protocol was increased 
stepwise depending on the severity of the reactions experi-
enced by each patient. In cases of repeated severe reactions 
(anaphylaxis), the desensitization protocol was interrupted. Pa-
Table 1. Cow's milk oral immunotherapy protocol (CM-OIT)
Day Milk dilution
Dose 
(mL)
Challenge 
(% milk protein)
  1 1/10 0.1 
  8 0.2 
15 0.4 
22 0.8 
29 Undiluted 0.1 
36 0.2
43 0.4
50 0.8
57 1
64 2
71 4 11 g baked goods (1.2% w/w)
78 10 15 g cold meat (2% w/w)
85 15 40 g milk chocolate (0.6% w/w)
92 20
99 25
106 30
113 40
120 50
127 60 66 mL liquid fermented milk (3% w/W)
135 70
142 80
149 100 100 g yogurt (3.3% w/w)
156 120 75 g cream cheese (5.3% w/w)
163 150
170 180
177 210
185 240 25 g goat and ewe's cheese (30% w/w protein)
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tients were considered to have successfully completed the pro-
tocol if they were able to tolerate a minimum of 200 mL of CM 
in less than 24 months.
Once the patients completed the OIT protocol, they main-
tained, during 1 year, a daily ingestion of 200 mL of commercial 
semi-skimmed UHT CM. If after 1 year the clinical desensitiza-
tion was sustained, the patients were authorized to have a non-
restricted diet.
Measurement of serum allergen-specific IgE and IgG4
Blood samples were withdrawn from the control subjects in-
cluded in the study and from the allergic patients before and af-
ter the OIT protocol was finished, and sera were analyzed for 
specific-IgE to CM, CN, α-La, and β-Lg, and CN-specific IgG4 
using the Phadia ImmunoCAP-System FEIA (Thermo Fisher 
Scientific, Barcelona, Spain).
In vitro stimulation of PBMCs
PBMCs were isolated by density-gradient separation (Ficoll-
Paque PLUS; GE Healthcare, Barcelona, Spain) from heparin-
ized venous blood. PBMCs (2×106 cells/mL) were cultured in 
vitro for 7 days at 37°C in 5% CO2 with medium alone (AIM-V, 
Biowest, Nuaillé, France), as negative control, or 200 μg/mL of 
β-casein (Sigma, St. Louis, MO, USA), with a lipopolysaccharide 
(LPS) level <0.4 ng/mg, as quantified by the Pierce LAL Chro-
mogenic Endotoxin Quantitation Kit (Thermo Scientific, 
Waltham, MA, USA). Phytohemagglutinin (PHA) (4 μg/mL; 
Sigma) was used as positive control.
Cytokine profile analyses
After 7 days of culture, levels of IL-5, IL-13, IL-10, IFN-γ, and 
TNF-α in supernatants were analyzed by a multiplex bead assay 
(BD cytometric bead array; BD Biosciences, San Diego, CA, 
USA), according to the manufacturer’s instructions. Cytokine se-
cretion was correlated to the standard of each of the human cyto-
kines (0-2,500 pg/mL). The GalliosTM flow cytometer (Beckman 
Coulter, Barcelona, Spain) was used to acquire data, which were 
analyzed by Beckman Coulter Kaluza and FCAP Array v3 (BD 
Biosciences) Software. Results are expressed as the amount of 
each cytokine detected after the stimulation with β-casein minus 
the amount detected after stimulation with the negative control.
Quantitative real-time PCR
Total RNA from the PBMCs cultured for 7 days was extracted 
using the Total RNA Isolation NucleoSpin® RNA II Kit according 
to the manufacturer’s instructions (Macherey-Nagel, Duren, 
Germany). The RNA template was qualitatively assessed and 
quantified using an Agilent 2100 Bioanalyzer (Agilent Technolo-
gies, Palo Alto, CA, USA) and a NanoDrop ND1000 instrument 
(Thermo Fisher Scientific), respectively. Reverse transcription 
reactions were performed following the manufacturer’s instruc-
tions with the Transcriptor First Strand cDNA Synthesis Kit 
(Roche, Manheim, Germany). RT-qPCR was performed in a Vi-
iATM 7 Real-Time PCR System (Applied Biosytems, Foster City, 
CA, USA) using a total of 6 ng of transcribed cDNA and Taq-
Man® Gene Expression Assay for the transcription factors: 
GATA3 (Human Assay ID Hs00231122m1), T-bet (ID Hs 
00203436m1), and FoxP3 (ID Hs01085834m1), according to the 
manufacturer’s recommendations. The hypoxanthine guanine 
phosphoribosyl transferase (HPRT) ID Hs02800695m1 was used 
as a reference gene. The amplification program used was: 1 cy-
cle of 10 minutes at 95°C, 40 cycles of 15 seconds at 95°C, and fi-
nally 1 cycle of 1 minutes at 60°C. All reactions were performed 
in triplicate. The mean value of the replicates for each sample 
was expressed as the quantification cycle (Ct). The relative gene 
expression values (RQ) were calculated using the delta delta CT 
method. RQ of more than 2 or less than 0.5 was established to be 
considered relevant.
Statistical analysis
Statistical analyses were performed using the GraphPad Prism 
5 software (San Diego, CA, USA). The nonparametric Mann-
Whitney test was used to compare between the groups, and the 
Wilcoxon t test was used to analyze differences between vari-
ables during OIT protocol. Results are presented as mean±
standard error of the mean (SEM) unless indicated. Differences 
were considered significant at the 95% confidence level.
RESULTS
Study population and CM-SBFC
Twenty allergic children (7 females and 13 males) aged be-
tween 1.5 and 11 years (mean 4.3 years) and 15 nonallergic 
children (8 females and 7 males) aged between 5 and 14 years 
(mean 8.7 years) were enrolled in the study (Table 2). There 
were not statistically significant differences regarding sex or age 
between any of the groups. Fifty-five percent of the CMA pa-
tients were allergic to other foods. Also, 45% of them had a past 
or current history of atopic dermatitis, 40% of asthma, and 30% 
of allergic rhinitis (Table 2). The baseline average specific IgE 
levels of the allergic group were 27.38 kU/L [0.4-100 kU/L] for 
CM, 26.45 kU/L [0.1-100 kU/L] for CN, 20.53 kU/L [0.1-94.1 kU/
L] for α-La, and 14.18 kU/L [0.5-82.3 kU/L] for β-Lg.
During the SBFC, the median threshold dose resulting in an 
allergic reaction was 4.0 mL (0.1-120 mL), with 60% of the pa-
tients developing anaphylaxis and 30% skin-related reactions 
(Table 2).
OIT protocol
Among the 20 patients included in the study, 14 (patients 1 to 
14 in Table 2) tolerated more than 200 mL of CM, as well as 
goat’s and ewe’s milk cheeses, in an average period of 18.9 
months (interval: 6-24 months), with 27.8 visits to the clinic of 
(interval 10-46 times). Fifty-seven percent of them experienced 
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mild dermatologic reactions during the desensitization proto-
col, with the most common symptoms being mouth itching 
and perioral erythema. Immunological changes associated 
with the OIT protocol were only assessed in these patients.
Four patients (patients 15 to 18 in Table 2) tolerated between 
35 and 80 mL of CM after 24 months of treatment and 40 visits 
(interval 32-48 times) to the clinic, on average. At the end of the 
24 months period, established as a time limit, this group was 
able to consume bakery, cold meat, and milk chocolate without 
developing adverse reactions. The reactions during desensiti-
zation of this particular group of patients were more severe, re-
porting strong abdominal pain and anaphylactic reactions. 
Two patients (patients 19 and 20) discontinued the study due to 
parental decision.
Immunological changes after the OIT protocol
As depicted in Fig. 1A, in patients that successfully completed 
the CM-OIT protocol (n=14) a significant (at least 4-fold), drop 
Table 2. Demographics, anamnesis, and response to cow's milk-OIT in cow's milk-allergic patients
Patient Age, yr Sex FA AD RN AS SBFCsymptoms
SBFC dose 
(mL milk)
Premedication
before ITO
OIT 
symptoms
OIT 
duration, 
mon
Visits to the 
Unit, No.
OIT 
tolerance 
(mL milk)
  1 1.5 F No No No No Skin 120 No Yes 24 10 ≥200
  2 5.9 F No No Yes Yes Anaphylaxis 15 No No 11 21 ≥200
  3 3.5 M Yes No No No Anaphylaxis 4 Yes Yes 20 37 ≥200
  4 2.4 M No No No No Skin 64 No Yes 14 27 ≥200
  5 3.8 M Yes Yes No No Anaphylaxis 2 No No 22 35 ≥200
  6 3 F No No No No Skin 90 No No 10 14 ≥200
  7 3.9 F Yes Yes Yes No Anaphylaxis 0.3 Yes No 18 42 ≥200
  8 3.1 M No No No No Skin 70 No No   6 16 ≥200
  9 7 M Yes No Yes Yes Anaphylaxis 0.3 Yes Yes 24 21 ≥200
10 4 F Yes Yes Yes Yes Skin 1 Yes Yes 24 46 ≥200
11 3.5 M Yes Yes Yes Yes Anaphylaxis 4 Yes Yes 24 43 ≥200
12 3 F No No No No Digestive 30 Yes Yes 24 44 ≥200
13 2.5 M Yes Yes No Yes Anaphylaxis 4 No No 20 24 ≥200
14 4 M Yes No No Yes Anaphylaxis 3 Yes Yes 24 10 ≥200
15 3.9 M Yes Yes No No Anaphylaxis 0.1 Yes Yes 24 37 60
16 3 M Yes Yes No No Anaphylaxis 1 Yes Yes 24 44 35
17 3.1 M No No No No Respiratory 2 No Yes 24 32 55
18 11 F No No Yes Yes Anaphylaxis 4 Yes Yes 24 48 80
19 10 M Yes Yes No Yes Anaphylaxis 10 No No NA NA NA
20 4.1 M No Yes No No Skin 30 Yes Yes NA NA NA
FA, other food allergies; AD, atopic dermatitis; RN, allergic rhinitis; AS, asthma; SBFC, single blind food challenge; NA, not applicable.
Fig. 1. Antibody response in CM-allergic patients. Serum-specific (A) IgE (kU/L) and (B) IgG4 (µg/L) to CM, α-La, β-Lg, and CN before (Orange blocks) and after (Blue 
blocks) the OIT protocol in the CM-allergic patients who tolerated at least 200 mL of cow’s milk (n=14). Bars represent mean±SEM. ***P<0.001; **P<0.01.
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in their CM, α-La, β-Lg, and CN-specific IgE levels was detected 
once the protocol was finished. Moreover, a significant increase 
from baseline was reached in the serum casein-specific IgG4 
concentration after the CM-OIT treatment (Fig. 1B).
Regarding the cellular response, a marked decrease in IL-13, 
IL-5 and IL-10 (statistically significant for IL-13 and IL-10) pro-
duction by PBMCs upon β-CN stimulation was observed when 
comparing initial and post-OIT levels (Fig. 2). Th1 cytokines, 
IFN-γ, and TNF-α were not detected. Interestingly, the baseline 
significant differences observed between allergic and nonaller-
gic children in IL-13 and IL-5 levels were no longer found once 
the protocol had finished (Fig. 2A and B). IL-10 production by 
β-CN-primed PBMCs from nonallergic donors was significantly 
higher (P<0.01) than that from CMA patients at the end of the 
protocol (Fig. 2C).
Analysis of the expression levels of the transcription factors 
Foxp3, GATA3, and T-bet in the successful patients (n=14), before 
and after the CM-OIT protocol, did not show any changes, with 
RQ values of 1.25 for FoxP3, 1.48 for GATA3, and 1.92 for T-bet.
DISCUSSION
In the present study, CM-desensitization (corresponding to 
tolerance to at least 200 mL of CM) was achieved by 70% of the 
children with IgE-mediated CM allergy initially included in the 
CM-OIT protocol. The desensitization rate was in the range of 
previous reports by González-Jiménez et al.,23 Vázquez-Ortiz et 
al.,24 and Meglio et al.,25 where 72%, 71.6%, and 71.4%, respec-
tively, of the children enrolled were desensitized to CM. A dis-
tinct feature of the reported protocol is the progressive intro-
duction of milk-containing foods into patients, diet: this al-
lowed food diversification and helped improve their quality of 
life while reducing the withdrawals from the therapy as they felt 
confident with the results of the intervention. It should be men-
tioned that children seemed to be not only desensitized to CM, 
but also to goat’s and ewe’s milk proteins. Several case reports 
on allergy to goat and sheep milk proteins in individuals previ-
ously desensitized to CM can be found in the literature.26,27 In 
fact, Rodríguez del Río et al.28 found, in patients who tolerated 
CM after CM-OIT, that 26% of them were still allergic to goat’s 
milk and ewe’s milk, with 47% of the positive oral food chal-
lenges graded as anaphylactic reactions.
Adverse reactions were usually controllable with a rate of oc-
currences lower than those reported in other CM-OIT proto-
cols.29-31 In any case, the side effects encountered during the 
treatment considerably lengthened the duration of the proto-
col, compared to what was originally planned, highlighting the 
importance of adapting the dosing regimen to the patient’s re-
sponse to the therapy. Similar results have recently been ob-
served in the course of an egg-OIT protocol, which had to be 
increased in approximately 9 months in relation to the original 
desensitization schedule.32 It is worthwhile to mention that 
some studies have documented that prolonged OIT treatments 
enhance the desensitization effect, suggesting that longer treat-
ment courses are more effective and possibly safer.31,33,34
Due to the length of the protocol and the strong familiar com-
mitment required for CM-OIT, the study was open-label and 
uncontrolled. However, the high baseline specific-IgE levels, as 
well as the adverse reactions observed during the therapy, sug-
gested that spontaneous CMA resolution was very unlikely in 
the population under study.35-37 The absence of a placebo group 
is justified by the results obtained in the placebo-controlled tri-
als performed by Skripak et al.17 and Longo et al.,18 in which 
none of the children included in the placebo group achieved 
even partial tolerance once the study had ended. In cases 
where the treatment applied had altered the natural course of 
CM-oral tolerance achievement, the authors would have either 
anticipated it or increased the threshold dose for patients that 
did not successfully complete the therapy.31,38 While the current 
protocol setting cannot confirm whether patients were tolerant 
Fig. 2. Cytokine production by β-CN-stimulated PBMCs. Levels of (A) IL-13, (B) IL-5, and (C) IL-10 (pg/mL) before (Orange blocks) and after (Blue blocks) the OIT proto-
col in the CM-allergic patients who tolerated at least 200 mL of CM (n=14). Gray blocks represent baseline cytokine production by β-CN-stimulated PBMCs in non-
allergic children (n=15). Bars represent mean±SEM. *P<0.05; **P<0.01; ***P<0.001.
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as CM was not withdrawn for ethical reasons, it should be not-
ed that all the patients considered successfully desensitized 
were on a free diet 1 year after the OIT protocol had ended.
Baseline specific-IgG4 levels increased after the therapy, as 
previously observed by a number of authors in other CM-OIT 
protocols,11,14,15,17 as well as in patients who spontaneously re-
covered from CMA,16,39 confirming the important role of this 
immunoglobulin in oral tolerance establishment. Concomitant 
with the increase in specific-IgG4, significantly reduced anti-
gen-specific-IgE production was found. Although a decrease in 
allergen-specific IgE production is commonly reported in most 
of the CM-OIT protocols described,19,24,30,38,40 other studies have 
reported no changes,17,20,25 which according to the authors, 
might be explained due to the shorter duration of their treat-
ments.
In accordance with previous publications,41,42 β-CN-primed 
PBMCs from CM allergic patients presented a significant Th2-
biased phenotype when compared to nonallergic individuals. 
In fact, enumeration of CN-specific IL-4- and IL-13-secreting T 
cells has been proposed as a promising tool to improve diagno-
sis of CMA.43 β-CN (27% of the total milk proteins) was chosen 
for PBMC stimulation as it represents a serious health risk in 
patients with CMA, since 75% of sera from patients with IgE-
mediated CMA against whole bovine CN have IgE directed 
against it.44 Furthermore, it is known that PBMCs from clinically 
reactive IgE-mediated CMA patients proliferate in response to 
LPS-free αS-, β-, and κ-CN, but not β-Lg.45 Importantly, signifi-
cant differences in baseline IL-5 and IL-13 levels between CMA 
and nonallergic children were no longer found once the treat-
ment had finished, demonstrating a transition toward a nonal-
lergic phenotype in the patients able to ingest ≥200 mL of milk 
without developing symptoms. To the best of our knowledge, 
there is only 1 other publication dealing with changes in the cy-
tokine response in milk allergic individuals subjected to CM-
OIT. Bedoret et al.21 found a shift from IL-4 and IL13 to IFN- 
production in patients desensitized to milk. However, in our 
protocol, detectable levels of β-casein-specific IFN- were not 
found.
In contrast to other OIT protocols toward egg32,46 or peanut,47 
IL-10 production by β-CN-stimulated PBMCs decreased, sug-
gesting not only Th2- and Treg cell impairment, as IL-10 pro-
duction is considered one of the main effectors responsible for 
the suppressive effect of Treg.48 Interestingly, Bedoret et al.21 
ruled out a role of allergen-specific FoxP3+ regulatory T cells in 
oral desensitization to CMA, suggesting that even when high 
doses of antigen are administered, the mechanism lies in aner-
gy or deletion, rather than suppression, of allergen-specific T 
cells. However, according to Shreffler et al.,49 allergen-specific 
and functionally suppressive Treg cells play a role in the resolu-
tion of milk allergy and could be important targets for immune 
monitoring. The authors reported that introduction of milk into 
the diet causes a decline in the frequency of Treg present in the 
peripheral blood, in parallel with an increase in the IgG4/IgE 
ratio and a reduced basophile response, which is attributed to 
Treg cells being recruited to the gastrointestinal tract by aller-
gen ingestion.49 Similarly, Varsheny et al.50 claimed that de-
creased Th2-cytokine and increased IgG4/Treg cell produc-
tions are the main immunologic changes that accompany the 
clinical efficacy of peanut OIT, even if they do not detect signifi-
cant changes in blood IL-10, which raises the hypothesis that 
blood cytokine levels do not reflect mucosal production of Treg 
or that mucosal and periphery Treg exert different functions. A 
further possibility is that induction of Treg is transient. Thus, 
Jones et al.47 found, in the course of peanut OIT, early genera-
tion of Treg and associated increased production of IL-10 by 
PBMCs eventually decreased after 12 months. In this respect, it 
should be noted that in our study, a long period of time re-
quired for a successful outcome of the treatment (average 18.9 
months) might have masked certain immunological events. On 
the other hand, in accordance with our results, Tiemessen et 
al.42 reported that CM-specific IL-10 production was signifi-
cantly higher in T-cell clones derived from children with persis-
tent CMA than from nonallergic children.
The lack of treatment-related changes in the expression of 
Treg (Foxp3), Th1 (Tbet), or Th2 (GATA3) transcription factors, 
despite the existence of measurable variations in cytokine pro-
duction, was already reported by Jones et al.47 and Perezábad et 
al.32 in their studies with peanut and egg OIT, respectively.
In conclusion, this report presents an efficient and safe milk-
OIT protocol characterized by the progressive introduction of 
milk-containing foods that may substantially improve the pa-
tient’s quality of life along the treatment course. Successful OIT 
was accompanied by an immune alteration characterized by a 
significant increase in antigen-specific IgG4 levels, a significant 
reduction in antigen-specific IgE concentration, and IL-5, and 
decreased IL-13 production by β-CN-stimulated PBMCs to-
ward a nonallergic phenotype. More research needs to be done 
in order to understand the role of IL-10 in CM-OIT. 
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